HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $984,834 | -80.3% | 25,781 | -81.4% | 0.00% | -83.3% |
| Q2 2023 | $4,990,465 | +586.2% | 138,355 | +626.5% | 0.02% | +500.0% |
| Q1 2023 | $727,290 | -87.8% | 19,044 | -81.8% | 0.00% | -90.6% |
| Q4 2022 | $5,958,340 | +154.0% | 104,716 | +96.4% | 0.03% | +88.2% |
| Q2 2022 | $2,346,000 | +468.0% | 53,329 | +425.3% | 0.02% | +240.0% |
| Q3 2021 | $413,000 | -58.2% | 10,153 | -53.3% | 0.01% | -54.5% |
| Q2 2021 | $987,000 | -52.7% | 21,732 | -56.6% | 0.01% | -66.7% |
| Q1 2021 | $2,087,000 | -20.5% | 50,054 | -18.6% | 0.03% | -10.8% |
| Q4 2020 | $2,626,000 | +713.0% | 61,492 | +401.0% | 0.04% | +640.0% |
| Q3 2020 | $323,000 | -29.6% | 12,273 | -28.3% | 0.01% | -28.6% |
| Q2 2020 | $459,000 | -65.0% | 17,111 | -76.8% | 0.01% | -82.9% |
| Q4 2019 | $1,310,000 | – | 73,897 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRAN CAPITAL MANAGEMENT, L.P. | 1,084,118 | $61,686,285 | 7.80% |
| SNYDER CAPITAL MANAGEMENT L P | 3,983,814 | $226,679,017 | 5.12% |
| First Light Asset Management, LLC | 923,119 | $52,525,471 | 4.88% |
| Redwood Investments, LLC | 441,809 | $25,138,932 | 3.37% |
| BERNZOTT CAPITAL ADVISORS | 444,728 | $25,305,023 | 3.27% |
| DOHENY ASSET MANAGEMENT /CA | 46,050 | $2,620 | 3.04% |
| Crawford Lake Capital Management, LLC | 42,171 | $2,399,530 | 2.75% |
| 2Xideas AG | 416,586 | $23,703,743 | 2.51% |
| Granite Investment Partners, LLC | 902,882 | $51,373,986 | 2.14% |
| HighMark Wealth Management LLC | 41,790 | $2,377,851 | 1.79% |